BC061237 Activators
BC061237, a gene expressed in diverse tissues such as bladder, limb mesenchyme, liver, nervous system, and skeletal musculature, is associated with various cellular processes crucial for development. The intricate network of tissue-specific expression suggests a multifaceted role for BC061237 in orchestrating gene expression and cellular functions in different anatomical structures.
Activation of BC061237 involves complex regulatory mechanisms influenced by various chemical modulators targeting distinct signaling pathways. For instance, inhibition of the TGF-β pathway by compounds like SB431542 and LY364947 may potentially activate BC061237, altering gene expression in tissues like limb mesenchyme. Modulation of the PI3K/Akt pathway by AZD5363 and GSK690693 presents another avenue for indirect activation, impacting BC061237 expression in tissues such as bladder and skeletal musculature. Inhibition of JNK and p38 MAPK pathways by SP600125 and SB203580, respectively, could influence BC061237 activation, particularly in tissues like the liver and nervous system. Additionally, targeting epigenetic mechanisms with SP2509, inhibiting BET proteins, might influence BC061237 expression in structures like the liver and nervous system. These examples underscore the complexity of BC061237 activation, showcasing its intricate regulation through multiple signaling pathways. Overall, the comprehensive understanding of BC061237 and its potential activators provides insights into its role in diverse tissues and offers avenues for further exploration into its regulatory networks and functional implications in development.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor affecting the JNK signaling pathway. Potential activator of BC061237 by inhibiting JNK pathway, potentially modulating gene expression in structures like liver and nervous system. SP600125's impact on JNK signaling could indirectly activate BC061237 by influencing cellular processes in tissues where BC061237 is expressed. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
MEK inhibitor affecting the MAPK pathway. Potential indirect activator of BC061237 by modulating the MAPK pathway, influencing gene expression and cellular processes in various tissues, including limb mesenchyme and skeletal musculature. U0126's impact on the MAPK pathway may indirectly activate BC061237 by altering downstream effects in tissues where BC061237 is expressed. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $105.00 $153.00 | 4 | |
TGF-β receptor inhibitor regulating TGF-β signaling. Potential activator of BC061237 by inhibiting the TGF-β pathway, potentially influencing gene expression in tissues like limb mesenchyme. LY364947's interference with TGF-β signaling could indirectly activate BC061237 by modulating downstream effects in tissues where BC061237 is expressed. | ||||||
SP2509 | 1423715-09-6 | sc-492604 | 5 mg | $284.00 | ||
BET bromodomain inhibitor targeting BET proteins. Potential activator of BC061237 by influencing epigenetic regulation, altering gene expression in structures like liver and nervous system. SP2509's impact on BET proteins could indirectly activate BC061237 by modulating epigenetic mechanisms and subsequently affecting its expression in tissues where BC061237 is active. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor affecting the MAPK pathway. Potential indirect activator of BC061237 by modulating the MAPK pathway, influencing gene expression in tissues including limb mesenchyme. PD98059's impact on the MAPK pathway may indirectly activate BC061237 by altering downstream effects in tissues where BC061237 is expressed. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor regulating p38 signaling pathway. Potential activator of BC061237 by inhibiting p38 MAPK pathway, potentially influencing gene expression in structures like liver and nervous system. SB203580's interference with p38 MAPK signaling could indirectly activate BC061237 by modulating downstream effects in tissues where BC061237 is expressed. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
ROCK inhibitor impacting the Rho/ROCK pathway. Potential indirect activator of BC061237 by modulating Rho/ROCK signaling, influencing gene expression in tissues such as bladder and skeletal musculature. Y27632's impact on the Rho/ROCK pathway may indirectly activate BC061237 by altering downstream effects in tissues where BC061237 is expressed. | ||||||
IWR-1-endo | 1127442-82-3 | sc-295215 sc-295215A | 5 mg 10 mg | $82.00 $132.00 | 19 | |
Wnt signaling inhibitor. Potential activator of BC061237 by inhibiting Wnt pathway, potentially influencing gene expression in structures like limb mesenchyme. IWR-1-endo's interference with Wnt signaling could indirectly activate BC061237 by modulating downstream effects in tissues where BC061237 is expressed. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
Akt inhibitor affecting the PI3K/Akt pathway. Potential indirect activator of BC061237 by modulating the PI3K/Akt pathway, influencing gene expression in tissues such as bladder and skeletal musculature. AZD5363's impact on the PI3K/Akt pathway may indirectly activate BC061237 by altering downstream effects in tissues where BC061237 is expressed. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
Akt inhibitor impacting the PI3K/Akt pathway. Potential activator of BC061237 by inhibiting the PI3K/Akt pathway, potentially influencing gene expression in structures like limb mesenchyme. GSK690693's interference with the PI3K/Akt signaling could indirectly activate BC061237 by modulating downstream effects in tissues where BC061237 is expressed. | ||||||